Jacobio Pharmalisted As 1167 Hkis A Pharmaceutical Company Focused On Developing Innovative Cancer Treatmentswith Over 20 Years Of Experiencethe Company Specializes In Novel Drugs That Target Critical Signaling Pathways In Cancersuch As Krastumor Immunityand Tumor Metabolismjacobio S Management Team Has A Strong Track Recordhaving Previously Led The Development Of China S First Targeted Anti Cancer Drug The Company Employs Two Main Platforms For Drug Developmentthe Induced Allosteric Molecule Discovery Platform And The Iadc Platformits Pipeline Includes Promising Compounds Like Glecirasiba Kras G12C Inhibitorand Sitneprotafiban Shp2 Inhibitorjacobio Emphasizes Combination Therapies To Enhance Treatment Effectivenessthe Company Is Also Active In Research And Developmentwith Over 360 Patent Applications Filed Globallyreflecting Its Commitment To Innovation In Cancer Medicinejacobio Pharma Aims To Improve Patient Outcomes Through Its Collaborative And Dedicated Approach To Drug Development
